Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunome, Inc. - Common Stock (NQ: IMNM )

9.210 +0.480 (+5.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 561,523
Open 8.840
Bid (Size) 9.200 (7)
Ask (Size) 9.210 (2)
Prev. Close 8.730
Today's Range 8.775 - 9.340
52wk Range 8.385 - 26.70
Shares Outstanding 62,416,845
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire

Performance

YTD
-12.54%
-12.54%
1 Month
-17.91%
-17.91%
3 Month
-34.40%
-34.40%
6 Month
-36.31%
-36.31%
1 Year
-62.16%
-62.16%

More News

Read More
Immunome to Present at Upcoming March Conferences
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Analyst Expectations For Immunome's Future
Via Benzinga
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Immunome, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Immunome Announces Pricing of Upsized Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
Curious about the stocks that are showing activity after the closing bell on Wednesday?
Via Chartmill
Immunome Announces Proposed Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
From Immunome, Inc.
Via Business Wire
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
From Hummingbird Bioscience
Via GlobeNewswire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
3 Small-Cap Stocks With Big Growth Potential
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
From Immunome, Inc.
Via Business Wire
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
From Immunome, Inc.
Via Business Wire
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
From Immunome, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
From Immunome, Inc.
Via Business Wire
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.